Galmed Pharmaceuticals (GLMD) Total Liabilities (2013 - 2025)

Galmed Pharmaceuticals' Total Liabilities history runs 13 years deep, the most recent figure standing at $2.8 million for Q4 2025.

• In Q4 2025, Total Liabilities rose 30.92% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $2.8 million (up 30.92% YoY), while the FY2025 annual figure was $2.8 million, up 30.92% from the prior year.
• Total Liabilities was $2.8 million for Q4 2025 at Galmed Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $7.4 million in Q1 2021 to a low of $1.6 million in Q2 2024.
• Historically, Total Liabilities has averaged $3.7 million across 5 years, with a median of $2.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities slumped 66.35% in 2024, then soared 55.79% in 2025.
• A 5-year view of Total Liabilities shows it stood at $6.1 million in 2021, then slumped by 48.62% to $3.1 million in 2022, then decreased by 12.36% to $2.8 million in 2023, then retreated by 20.98% to $2.2 million in 2024, then surged by 30.92% to $2.8 million in 2025.
• The last three Total Liabilities figures came in at $2.8 million (Q4 2025), $2.5 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.